证券代码：603235 证券简称：天新药业 公告编号：2024-050 目前，公司已对相关工作进行了妥善安排。公司拥有完善的组织架构和规 范的治理体系，公司将按照《公司法》《上海证券交易所股票上市规则》《上 市公司治理准则》及《公司章程》等法律法规和相关制度规范运作。截至本公 告披露日，公司其他董事、监事和高级管理人员均正常履职，公司控制权未发 生变化，董事会运作正常，生产经营管理情况正常，上述事项不会对公司正常 生产经营产生重大影响。 截至本公告披露日，公司尚未知悉上述事项的进展及结论，公司将持续关 注上述事项的后续情况，并严格按照有关法律、法规和规范性文件的规定及时 履行信息披露义务并提示相关风险。公司指定的信息披露媒体为《中国证券报》 《上海证券报》《证券时报》《证券日报》及上海证券交易所网站 （www.sse.com.cn），公司发布的信息均以在上述指定媒体刊登的信息为准。 敬请广大投资者理性投资，注意投资风险。 江西天新药业股份有限公司 关于公司实际控制人、董事长被留置的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律 ...

江西天新药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 证券代码：603235 证券简称：天新药业 公告编号：2024-049 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定：回购股份期间，上市公司应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份情况公告如下： 2024 年 10 月，公司未实施股份回购。 截至 2024 年 10 月 31 日，公司已累计回购股份 2,609,720 股，已回购股份占 公司总股本的比例为 0.5961%，回购的最高价格为 28.00 元/股，最低价格为 19.17 元/股，已支付的总金额为 60,001,880.46 元（不含交易费用）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/23 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-048 江西天新药业股份有限公司 关于 2024 年第三季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司 2024 年第三季度经 营数据（未经审计）公告如下： 一、 2024年第三季度主要经营数据 1、主营业务分产品情况 单位：元 币种：人民币 | 产品分类 | 2024 | 年 月收入 7-9 | 2023 | 年 7-9 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | 族维生素 B | | 401,195,030.12 | | 329,640,370.90 | | 21.71% | | 其他维生素 | | 109,653,603.34 | | 23,673,363.41 | | 363.19% | | 精细化工品 | | 29,978,803.7 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥546,966,616.93, representing a 49.12% increase compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥149,314,516.53, an increase of 80.01% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥138,406,863.87, reflecting a 127.04% increase compared to the previous year[2] - Basic earnings per share for Q3 2024 were ¥0.34, up 78.95% from the same quarter last year[3] - Total operating revenue for the first three quarters of 2024 reached CNY 1,613,579,810.79, an increase of 8.5% compared to CNY 1,487,340,403.10 in the same period of 2023[13] - Net profit attributable to shareholders of the parent company for the third quarter of 2024 was CNY 494,482,977.97, up 19.7% from CNY 412,902,988.52 in the third quarter of 2023[17] - Basic and diluted earnings per share for the third quarter of 2024 were both CNY 1.13, compared to CNY 0.94 in the same quarter of 2023[17] - The net profit for the first three quarters of 2024 was ¥525,646,257.31, up 18.7% from ¥442,742,585.20 in the previous year[26] - The earnings per share for the first three quarters of 2024 was ¥1.20, compared to ¥1.01 in the same period of 2023, representing a growth of 18.8%[26] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥5,272,368,099.96, a 3.58% increase from the end of the previous year[3] - The equity attributable to shareholders increased by 5.29% to ¥4,456,661,809.73 compared to the end of the previous year[3] - The company's total assets increased to CNY 5,272,368,099.96, compared to CNY 5,090,159,178.34 at the end of the previous quarter[12] - The total liabilities decreased to CNY 815,706,290.23 from CNY 857,212,016.90 in the previous quarter[12] - The company's total current liabilities decreased to approximately ¥236.42 million as of September 30, 2024, down from ¥419.07 million at the end of 2023, indicating improved liquidity[23] - The total liabilities decreased to ¥599,495,071.28 from ¥809,423,974.11, reflecting a reduction of approximately 26%[24] - The total equity increased to ¥4,526,766,465.94, compared to ¥4,271,888,538.31, marking a growth of about 6%[24] Cash Flow - The net cash flow from operating activities for the year-to-date decreased by 24.81% to ¥439,852,434.45[2] - The net cash flow from operating activities for the first three quarters of 2024 was approximately ¥439.85 million, down 24.7% from ¥584.96 million in the same period of 2023[20] - The cash flow from operating activities generated a net amount of ¥183,023,573.88, down from ¥417,128,598.64 in the previous year[27] - The company's cash and cash equivalents at the end of September 2024 were approximately ¥1.62 billion, down from ¥2.40 billion at the end of 2023, reflecting a decrease of 32.3%[21] - The cash and cash equivalents at the end of the period decreased to ¥1,574,870,618.23 from ¥2,306,668,288.63, a decline of approximately 31.7%[28] - The net cash flow from financing activities was approximately -¥278.71 million in the first three quarters of 2024, compared to -¥186.26 million in the same period of 2023, indicating a worsening cash flow situation[21] Research and Development - Research and development expenses for the first three quarters of 2024 amounted to CNY 72,715,184.45, representing a 16.4% increase from CNY 62,670,894.08 in the same period of 2023[15] - The company reported a significant increase in R&D expenses to ¥30,744,470.05, compared to ¥29,148,881.33 in the same period last year, indicating a focus on innovation[25] Shareholder Information - The company has a total of 15,544 common shareholders at the end of the reporting period[8] - The largest shareholder, Xu Jiangnan, holds 46.51% of the shares, totaling 203,603,970 shares[7] - The company has no significant changes in the participation of major shareholders in margin trading or stock lending[8] Operational Insights - The increase in revenue and profit was primarily driven by higher sales of vitamin products during the reporting period[6] - Non-recurring gains and losses for the period totaled ¥10,907,652.66, with significant contributions from government subsidies and fair value changes of financial assets[5] - There are no other significant reminders regarding the company's operational situation during the reporting period[9] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[29]

江西天新药业股份有限公司 投资者关系活动记录表 编号：2024-003 | --- | --- | --- | |----------------|---------------------------------------|------------------------------------------------------------| | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □其他 : | | | 参与单位名称及 | 线上参与公司 | 年半年度业绩说明会的全体投资者 | | 人员姓名 | | | | 时间 | 2024 年 10 月 | 15:00-16:00 | | 地点 | 上证路演中心（ | http://roadshow.sseinfo.com/ ） | | 上市公司接待人 | 董事、总经理：余小兵 独立董事：刘路遥 | | | 员姓名 | 财务总监：罗雪林 | | | | 董事会秘书：董忆 | | | 投资者关系活动 | | 问： ...

证券代码：603235 证券简称：天新药业 公告编号：2024-047 江西天新药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 具体内容详见公司于 2024 年 1 月 23 日、2024 年 1 月 30 日和 2024 年 6 月 20 日刊登在上海证券交易所（www.sse.com.cn）及公司指定披露媒体上的《关于以集 中竞价交易方式回购股份方案的公告》（公告编号：2024-003）、《关于以集中竞 价交易方式回购股份的回购报告书》（公告编号：2024-008）和《关于 2023 年年 度权益分派实施后调整回购股份价格上限的公告》（公告编号：2024-037）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定：回购股份期间，上市公司应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份情况公告如下： 2024 年 9 月，公司未实施股份回购。 截至 20 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-046 江西天新药业股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 9 月 26 日（星期四）至 10 月 9 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过江西天新药业股份有限 公司（以下简称"公司"）邮箱 ir@txpharm.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 公司已于 2024 年 8 月 31 日发布公司 2024 年半年度报告，为便于广大投资 者更全面深入地了解公司 2024 年半年度的经营成果、财务状况，公司计划于 2024 年 10 月 10 日（星期四）下午 15:00-16:00 举行 2024 年半年度业绩说明会，就投 资者关心的问题进行交流。 独立董事：刘路遥先生 财务总监：罗雪林先生 董事会秘书：董忆先生 （如有特殊情况，参会人员可能进行调整） 四、投资者参加方式 一、说 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [12]. Core Views - The vitamin market is expected to continue its upward trend, with the company showing promising growth potential due to the orderly advancement of new projects [1][5]. - The company's financial performance in the first half of 2024 shows improvement, driven by a moderate recovery in vitamin demand and stable raw material prices [2][5]. Financial Summary - The company's revenue for 2022 was 2,305 million, which decreased to 1,882 million in 2023, but is projected to rise to 2,547 million in 2024, reflecting a year-on-year growth rate of 35.3% [1]. - The net profit attributable to the parent company was 622 million in 2022, dropping to 476 million in 2023, with an expected recovery to 757 million in 2024, marking a 59.0% year-on-year increase [1]. - The company's return on equity (ROE) is projected to improve from 11.2% in 2023 to 15.9% in 2024 [1]. Market and Product Insights - The company's vitamin B segment generated revenue of 891 million in the first half of 2024, with a gross margin of 48.24%, an increase of 8.37 percentage points year-on-year [2][5]. - The prices of VB1 and VB6 have stabilized and are expected to continue rising, contributing positively to the company's performance [5]. - The company is advancing multiple projects, including a 7,000-ton vitamin B5 project and a 1,000-ton vitamin A project, which are expected to enhance product structure and performance [5][6]. Future Projections - The company is projected to achieve revenues of 25.47 billion, 30.71 billion, and 35.34 billion from 2024 to 2026, with corresponding net profits of 7.57 billion, 9.20 billion, and 11.30 billion [5][6]. - The expected earnings per share (EPS) are forecasted to be 1.73, 2.10, and 2.58 for the years 2024, 2025, and 2026, respectively [5][6].

重要内容提示： | 回购方案首次披露日 | 2024/1/23 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 1 | 22 | 日~2025 | 年 | 1 | 21 | 日 | | 预计回购金额 | 60,000,000 元~120,000,000 元 □减少注册资本 | | | | | | | | 回购用途 | √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 2,609,720 股 | | | | | | | | 累计已回购股数占总股本比 | 0.5961% | | | | | | | | 例 | | | | | | | | | 累计已回购金额 | 60,001,880.46 元 | | | | | | | | 实际回购价格区间 | 19.17 元/股~28.00 元/股 | | | | | | | 证券代码：603235 证券简称：天新药业 公告编号：202 ...

证券代码：603235 证券简称：天新药业 公告编号：2024-043 江西天新药业股份有限公司 关于 2024 年第二季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司 2024 年第二季度经 营数据（未经审计）公告如下： 一、 2024年第二季度主要经营数据 1、主营业务分产品情况 特此公告。 单位：元 币种：人民币 | 产品分类 | 2024 | 年 月收入 4-6 | 2023 | 年 4-6 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | 族维生素 B | | 481,009,752.01 | | 466,642,684.95 | | 3.08% | | 其他维生素 | | 52,681,773.93 | | 36,673,511.79 | | 43.65% | | 精细化工品 | | 29,002,87 ...